An Overview of Severe Myalgic Encephalomyelitis.
Vink, Mark, Vink-Niese, Alexandra · Journal of clinical medicine · 2026 · DOI
Quick Summary
This article reviews what we know about severe ME/CFS, a serious illness that can leave people completely bedbound and dependent on caregivers. Currently, there is no blood test or scan that can diagnose ME/CFS, though a special two-day exercise test can help document the problem. The authors emphasize that severe ME/CFS is a major medical condition that has received very little research funding, and there are currently no proven treatments available.
Why It Matters
This article highlights the severe disability experienced by ME/CFS patients, particularly those with the most serious forms of the illness, and underscores the urgent need for research funding and treatment development. It brings attention to the growing number of post-COVID patients developing ME/CFS, making this a timely public health concern. The editorial's call for advanced medical research directly addresses the unmet medical needs of patients who currently have no effective treatments.
Observed Findings
- ME/CFS is a clinical diagnosis made in the absence of a specific diagnostic test.
- 2-day cardiopulmonary exercise testing can document abnormal exercise response in research and disability contexts.
- Severe ME/CFS causes profound disability, with some patients bedbound 24/7 and requiring 24-hour care.
- Some severely affected patients experience life-threatening malnutrition requiring tube feeding.
- COVID-19 has led to a sharp increase in post-infectious disease cases meeting ME/CFS criteria.
Inferred Conclusions
- Decades of underfunding have left ME/CFS without any effective pharmacological treatments despite its severe impact on patients' lives.
- Dedicated research using advanced medical technologies is necessary to understand the underlying disease mechanisms of ME/CFS.
- The post-COVID pandemic has created an urgent need to address ME/CFS as a significant public health concern.
- Current diagnostic approaches rely on clinical assessment rather than objective biomarkers, limiting early detection and research standardization.
Remaining Questions
- What are the specific biological mechanisms underlying ME/CFS and its post-exertional malaise response?
- How can researchers develop objective biomarkers to enable earlier diagnosis and disease monitoring?
- Which advanced medical technologies and research approaches are most likely to yield effective treatments?
- How do post-COVID ME/CFS cases compare to ME/CFS from other infectious origins in terms of mechanisms and prognosis?
What This Study Does Not Prove
This editorial does not present new research data, clinical trials, or experimental findings—it is a literature review and opinion piece. It does not establish what causes ME/CFS, propose specific mechanisms of disease, or test any particular treatment. The observations about severe ME/CFS severity and current lack of treatments reflect the authors' synthesis of existing literature rather than new evidence.
Topics
Tags
Metadata
- DOI
- 10.3390/jcm15020805
- PMID
- 41598742
- Review status
- Editor reviewed
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 7 April 2026